Assessment — idea-023

A wound irrigation system for US professional wound care. It pairs a per-patient bag of saline preserved with hypochlorous acid (HOCl) with a single-use, hand-squeezed three-nozzle spray head that has an integral splash shield and fits only this maker's bag. It is a variant of "Aquaceso", which a Danish contact of the owner referred in.

This file carries no confidence tags. It cites them: [claim N: tag] reads claim N of the candidate file with the tag it carries there, and check_assessment.py refuses a citation that disagrees. It moves no score, no stage: and no status:.

How these gradings were made. Read this first, because they are not prospective. This is the first assessment of idea-023. It was stated on 2026-10-04 against P1 per-patient HOCl bag, the shape recorded in the loop record as a redesign. Every consequence class below was set on 2026-10-04, after the Verifier had tagged claims 1-194. The only exception is claim 195unverified, which this file appended (pillar B2 The single-use head is keyed to this…) and which nobody has checked yet. So every grading here is a reconstruction, and the graded: dates cannot show otherwise. The damage was limited the same way the loop record limits it. Each class was set from what the register's "If it is false" column and the binding chairs' positions say breaks, not from how the tag came back. No claim under any pillar is refuted, so no grading here was chosen to keep a refutation away from a fatal pillar.

Register coverage made several rests on: lists wider than this file would have drawn them. The checker requires every claim cited in a live row of the loop record's assumption register to sit under some pillar. That is 116 claims, plus claim 195unverified. Each claim was placed where its own row's "If it is false" column lands. Where that pulled in a verified claim the pillar would survive without, and so lifted its standing, the last section says so. That applies to B1 US hospitals, B3 The opened per-patient bag holds, B4 The hand-squeezed head works and is safe to…, B6 Nobody else's rights stop a US sale of the… and B7 Neither half needs more than a 510.

What the referrer asked, and where each answer sits. The referrer asked about the clinical, regulatory, intellectual-property and market position. In this file the clinical position is mainly B5 Clinicians have a reason to choose it that…, with B4 The hand-squeezed head works and is safe to… for safety in use. Regulatory is B7 Neither half needs more than a 510, plus B3 The opened per-patient bag holds for the bag's label. Intellectual property is B6 Nobody else's rights stop a US sale of the…, with B2 The single-use head is keyed to this… for whether the keyed fit can be owned. The US market is B1 US hospitals and B2 The single-use head is keyed to this…, and Denmark and Europe are B8 The referrer's home market is open. Under…. Every European and Danish claim in the file is unconfirmed, because no connector here reaches a European source. B8 The referrer's home market is open. Under… says so rather than borrowing the US result.

The bet

A wound nurse cleans a chronic wound at each dressing change. She may work in a US hospital, an outpatient wound clinic, a skilled nursing facility, or on a home health visit. Today she uses saline and a syringe, or pours from a bottle or bag of an HOCl cleanser that is already cleared claim 6verified. The bet is that her employer will buy a system instead. It has two parts:

• The bag. A sterile bag of saline preserved with HOCl, opened once per patient and used over a labelled in-use period. That is how the one cleared HOCl irrigation bag is labelled claim 122verified.
• The head. A fresh single-use spray head at every session. The nurse squeezes it to reach the wound-cleansing pressure range, and its shield keeps the spray off her.

Nobody pays for the system separately:

• Medicare's home-equipment benefit does not cover wound cleansers claim 29verified.
• In the facility settings, supplies are paid inside a bundled payment claim 65verified, claim 66verified, claim 67verified.

So the facility or agency pays out of its own supply budget. The price has to beat the cost of saline and a syringe, or of an HOCl bottle, on cost-in-use claim 161unconfirmed.

The money is meant to come from the head: one per session, fitting only this maker's bag claim 162unconfirmed, claim 195unverified. The bag is a parity product. On the label, HOCl has one job, which is to preserve a bag that is opened more than once claim 119verified. The label makes no claim that HOCl does anything in the wound.

This shape came out of a redesign. The original single-use kit ran into two problems:

• FDA's 2023 proposal accepts a preservative only in a nonsterile wash or a multiple-use wash for one patient claim 119verified.
• A hand-squeezed bag peaks at about 4 psi claim 143verified.

Two things are unknown and sit under the whole bet: who makes Aquaceso, and whether the referrer can bring its rights claim 2unconfirmed, claim 3unconfirmed.

The shapes it is not. Each one survives a different pillar failing. None is chosen here. This /pursue run has spent its pivot budget, so moving to any of them is the owner's decision.

• (a) The head sold for any maker's bag, under the Class I irrigating-syringe route claim 17verified. This shape survives B2 The single-use head is keyed to this… failing. It also survives B3 The opened per-patient bag holds failing, because an incumbent's bag already carries a multiple-use label claim 122verified. It has no pull-through, and it does not survive B1 US hospitals or B4 The hand-squeezed head works and is safe to….
• (b) The bag alone, as a fifth or later HOCl wound solution. It survives B2 The single-use head is keyed to this…, B4 The hand-squeezed head works and is safe to… and the hardware half of B6 Nobody else's rights stop a US sale of the…. FDA has cleared 35 wound-cleanser solutions under the same product code in two years claim 158unconfirmed, which is why the bag is graded a parity product. It does not survive B3 The opened per-patient bag holds.
• (c) An incumbent HOCl maker fills the bag, under licence or co-brand. This shape survives the supply half of B3 The opened per-patient bag holds and the solution half of B6 Nobody else's rights stop a US sale of the…: supply and patents point at the same incumbent from opposite sides claim 190unconfirmed, claim 149verified. It gives away the bag's margin and possibly the keyed fit.
• (d) The original single-use kit, with a filled bag in every kit. It was set aside because FDA's proposed rule calls a preservative in a sterile single-use wash inappropriate claim 119verified. It would come back only if B3 The opened per-patient bag holds fails and the rule is never finalized in the form proposed.
• (e) A powered head. This shape survives B4 The hand-squeezed head works and is safe to…'s pressure leg failing. It changes the route to market (FDA's jet-lavage regulation) and the cost of every head.
• (f) Saline without HOCl, which is the referred device's own irrigant. It needs no clinical belief in HOCl (B5 Clinicians have a reason to choose it that…). But an unpreserved bag cannot be opened more than once, so this is shape (d) without the preservative.

One shape question is open, and it is the owner's to answer. Neither intended_use: nor mechanism: says who holds an opened bag between outpatient clinic visits. There are three options: the clinic keeps it, the patient takes it home, or it is thrown away after each visit. Each option changes the label. B1 US hospitals's cost per session and B3 The opened per-patient bag holds's in-use period both turn on the choice. The loop record handed this to the owner (REQ-0235 For the P1 per-patient HOCl bag), and this file does not make it.

Pillars

There are eight. One is graded fatal: somebody has to pay more per session than for saline and a syringe, and enough to cover the cost (B1 US hospitals). Five are reshaping. Each of them names a neighbouring shape above, and that shape survives the pillar failing. Two are costly: the clinical reason to choose the system (B5 Clinicians have a reason to choose it that…), and the Danish and European route (B8 The referrer's home market is open. Under…). The last section argues against three of these gradings.

• B1 US hospitals US hospitals, outpatient wound clinics, skilled nursing facilities and home health agencies, buying out of a supply budget that sits inside a bundled payment and with no separate Medicare payment for the product, pay a per-session price for one single-use head plus its share of a per-patient bag that is above saline with a syringe or a bottle of HOCl cleanser, and that price covers the fully loaded cost of a session at the business case's volume and at one-tenth of it — consequence: fatal — graded: 2026-10-04 — rests on: claim 161unconfirmed, claim 188unconfirmed, claim 117unconfirmed, claim 37unconfirmed, claim 36unconfirmed, claim 131unconfirmed, claim 165unconfirmed, claim 166unconfirmed, claim 34verified, claim 68verified, claim 69verified, claim 105verified, claim 103verified, claim 104verified, claim 29verified, claim 65verified, claim 66verified, claim 67verified, claim 164verified — settled by: twenty structured calls with US value-analysis committees and supply-chain buyers on the instrument Commercial designed under REQ-0225 Design, which carries claims 161 and 162 (fieldwork the owner must authorise), with the Vashe Federal Supply Schedule contract price for claim 131unconfirmed retrieved first; the per-session cost test (claim 188unconfirmed) follows once REQ-0244 For P1 gives a price and volumes and a bill of materials exists — analogs: [analog: acute-chronic-wound-cleansing-irrigation.reference-products.analog-premium-single-use-accessory-inside-bundled-supply-budget] — cost: cheap — in plain words: Hospitals, wound clinics, nursing homes and home-care agencies in the United States must pay more for each cleaning session with this system than for saline and a syringe. They pay from their own supply budgets, because no insurer pays for it separately, and the price has to cover what a session costs to make. If they will not pay more, nothing here earns money.
• B2 The single-use head is keyed to this… The single-use head is keyed to this maker's bag, and buyers accept it. One connector can be made that accepts only this maker's head, reseals between sessions, and is acceptable to FDA within a 510(k) or exempt route. US value-analysis committees and group purchasing buyers put on formulary a head that fits only its own maker's bag, and do not require it to fit bags they already stock — consequence: reshaping — graded: 2026-10-04 — rests on: claim 195unverified, claim 162unconfirmed — settled by: Regulatory's answer to REQ-0255 P1's mechanism makes the single-use head… (whether FDA accepts a non-standard, maker-keyed port on a wound-irrigation bag) and Technology's answer to REQ-0234 In the P1 reference design (whether keying and resealing can share one connector), both answerable from records and engineering judgement; the buyer half is carried by the same calls that settle B1 US hospitals — cost: cheap — in plain words: The single-use spray head has to fit only this maker's bag, and the bag's port has to seal itself between sessions. The United States regulator has to accept a connector that is not the standard one, and hospital buyers have to accept a head that will not fit the bags they already stock. If any of that fails, the head becomes an accessory for anyone's bag and the bag has to sell on its own, which is a different business.
• B3 The opened per-patient bag holds The opened per-patient bag holds, and someone will make it. HOCl-preserved saline in a bag that a new head re-enters at every session stays within its free available chlorine, pH and preservative-effectiveness specification. Wound organisms introduced at the port do not survive in it. Both hold on three lots aged to the end of shelf life, for an in-use period at least as long as the usual gap between sessions in every setting sold to. A filler that does not itself sell HOCl wound cleansers in the US will make the bag with a keyed port — consequence: reshaping — graded: 2026-10-04 — rests on: claim 167unconfirmed, claim 177unconfirmed, claim 168unconfirmed, claim 174unconfirmed, claim 189unconfirmed, claim 163unconfirmed, claim 126unconfirmed, claim 127unconfirmed, claim 71unconfirmed, claim 128unconfirmed, claim 190unconfirmed, claim 119verified, claim 122verified, claim 176verified, claim 169verified, claim 178verified, claim 125verified, claim 6verified, claim 110verified — settled by: REQ-0228 Retrieve the labelled storage condition first, the Puracyn Plus labelled in-use period and port design (one retrieval, named by three chairs as their cheapest move); then a short in-use run on prototype bags from a candidate filler, which needs a filler request for information that the owner must authorise — cost: project — in plain words: Once a bag of the hypochlorous-acid saline is opened, it is reconnected to a fresh head at every session. It has to stay clean and within its chemical specification for longer than the usual gap between one patient's sessions, and a company that is not a competitor has to be willing to fill it. If the opened bag cannot be kept, it cannot be labelled for repeated use. Under the United States regulator's proposed rule, the bag would then have no label it can carry.
• B4 The hand-squeezed head works and is safe to… The hand-squeezed head works and is safe to use. Fed from the bag through its check valve, it holds 4-15 psi at its working distance for every operator, from the first to the last 10% of the bag. It removes slough and debris no worse than a 35 mL syringe with a 19G angiocatheter. After sterilization and ageing it survives twice a full session's squeeze cycles. It has no metal in its wetted path. Under the shield it keeps breathing-zone chlorine at or below the 1 ppm Table Z-1 ceiling, with droplet concentration no higher than without the shield — consequence: reshaping — graded: 2026-10-04 — rests on: claim 145unconfirmed, claim 172unconfirmed, claim 192unconfirmed, claim 147unconfirmed, claim 191unconfirmed, claim 148unconfirmed, claim 51unconfirmed, claim 143verified, claim 86verified, claim 70verified, claim 16verified, claim 88verified, claim 89verified, claim 99verified, claim 100verified — settled by: a bench rig on a prototype head of defined geometry (REQ-0249 For the P1 head assembly, REQ-0239 For the P1 reference head) measuring delivered pressure across operators, cycle life, and chlorine and droplets in the breathing zone; the in-hand clinical comparison (claim 172unconfirmed) comes after and needs funding — cost: project — in plain words: Squeezed by hand, the head has to deliver the pressure range that wound-care guidance recommends, every time and for every nurse. It has to clean at least as well as a syringe, last a full session, and not put chlorine into the air the nurse breathes. If it cannot do this by hand, it needs a pump or a redesign, which changes the device and its route to market.
• B5 Clinicians have a reason to choose it that… Clinicians have a reason to choose it that the product can carry. The label may not say that HOCl acts in the wound. So either US wound clinicians already believe that HOCl cleansing beats saline, or the shield measurably cuts splatter on the irrigator with no detectable chlorine. And irrigating at room temperature instead of warmed costs nothing clinically — consequence: costly — graded: 2026-10-04 — rests on: claim 116unconfirmed, claim 141unconfirmed, claim 44unconfirmed, claim 42unconfirmed, claim 10unconfirmed, claim 173unconfirmed, claim 1unconfirmed, claim 93verified, claim 87verified, claim 107verified, claim 142verified, claim 101verified, claim 94verified, claim 48verified, claim 175verified — settled by: the desk search already filed as research row acute-chronic-wound-cleansing-irrigation.3.us-clinician-hocl-belief-and-cleanser-purchase-influence, then twenty structured calls with US wound clinicians on the clinician-belief study designed under REQ-0226 Design the primary research that would… (fieldwork the owner must authorise); the Urgo randomized trial of Vashe against saline (NCT07440797) reads out later and is not something anyone here can speed up — cost: cheap — in plain words: Nurses and wound doctors need a reason to pick this over saline and a syringe. The label cannot say that hypochlorous acid helps wounds heal, and no adequately sized trial showing that it does has been found. So the reason has to be their own belief, or a shield that measurably keeps splash off them. If neither holds, the system still works but sells on convenience alone, for less.
• B6 Nobody else's rights stop a US sale of the… Nobody else's rights stop a US sale of the head and the bag at launch. Counsel finds that no in-force claim or design reads on a defined head geometry, or a licence or design-around exists. That covers the Schultz utility and design patents, Medaxis, the '811 and '457 leads and the pending CareFusion applications. No Urgo or Sonoma solution claim reads on the chosen formulation. The unsearched landscape for the squeeze chamber and the keyed connector holds no blocking patent. The referrer can bring whatever Aquaceso rights the head needs — consequence: reshaping — graded: 2026-10-04 — rests on: claim 3unconfirmed, claim 155unconfirmed, claim 193unconfirmed, claim 194unconfirmed, claim 52verified, claim 85verified, claim 149verified, claim 150verified, claim 83verified, claim 157verified, claim 56verified, claim 151verified, claim 152verified, claim 181verified, claim 182verified, claim 183verified, claim 184verified, claim 185verified, claim 186verified, claim 187verified, claim 154verified, claim 156verified, claim 81verified — settled by: first the referrer's answer on who makes and owns Aquaceso (REQ-0224 Ask the referrer and REQ-0208 Obtain from the referrer, one message the owner sends); then the head geometry from REQ-0249 For the P1 head assembly, the landscape searches REQ-0212 Run a recorded and REQ-0248 Run a recorded US landscape, and counsel's read of the named families against that geometry, which the owner must engage — cost: project — in plain words: Several patents on splash shields and wound-washing hardware are still in force, some until about 2040, and a competitor holds a patent family on stabilised hypochlorous acid. Nobody has yet checked any of them against a defined head, because the head has not been drawn. A patent lawyer has to find a clear path or a licence, and the person who referred the idea has to be able to bring the rights to the original design. If not, the head must be redesigned, licensed or delayed, or the bag sold for someone else's hardware.
• B7 Neither half needs more than a 510 Neither half needs more than a 510(k). FDA places the separately sold, hand-squeezed head in 21 CFR 880.5475 or 880.6960 and does not require a De Novo. The bag stays a 510(k) wound wash under product code FRO with HOCl as a preservative, because proposed rule 2023-26209 is either not finalized against it or finalized with HOCl in its Class II low-AMR-concern tier. Both halves clear on bench and animal data, without clinical data — consequence: reshaping — graded: 2026-10-04 — rests on: claim 180unconfirmed, claim 179verified, claim 12verified, claim 120verified, claim 121verified, claim 4verified, claim 13verified, claim 14verified, claim 17verified, claim 124verified, claim 144verified — settled by: REQ-0254 Search openFDA 510, a records search for any separately sold, hand-operated, container-fed head cleared under FQH or KYZ; only FDA settles the head, through a 513(g) request or a Pre-Submission, and either one discloses the opportunity outside the organisation, which makes it the owner's decision — cost: project — in plain words: In the United States, the bag should clear by copying the hypochlorous-acid wound washes already on the market, and the head as an ordinary irrigation device, both without a clinical trial. Only the regulator can confirm the head, and asking means disclosing the project. If the head needs a new classification, or the regulator's pending rule turns against the bag, the timeline and the money needed both change, and so may who can carry the programme.
• B8 The referrer's home market is open. Under… The referrer's home market is open. Under EU MDR Annex VIII, an HOCl irrigation solution with HOCl as a preservative is Class IIb, not Class III, with a notified-body precedent. Danish regional tenders, Region Nordjylland's being the one in the file, admit the bag on its own and a head on its own, and weigh at least one criterion other than price. No European patent in force in Denmark reads on the head, the shield, the solution or the system — consequence: costly — graded: 2026-10-04 — rests on: claim 21unconfirmed, claim 22unconfirmed, claim 112unconfirmed, claim 135unconfirmed, claim 26unconfirmed, claim 113unconfirmed, claim 115unconfirmed, claim 132unconfirmed, claim 133unconfirmed, claim 134unconfirmed, claim 170unconfirmed, claim 171unconfirmed, claim 159unconfirmed — settled by: a human download of the Nordjylland tender documents and award notice from TED or EU-Supply (REQ-0201 For Region Nordjylland's joint wound tender, REQ-0236 For Region Nordjylland's joint wound tender), because the TED host blocks automated fetch; then a notified-body certificate search and a European patent search, which no connector here reaches — cost: cheap — in plain words: In Denmark and the rest of Europe, the bag should fall in the second-highest of the four device risk classes rather than the highest. Danish regional tenders should let the bag and the head bid separately and score more than price, and no European patent should block the product. None of this has been checked against a primary source, because the tools here reach only American records. If it fails, Denmark comes later or costs more, and the American plan is unchanged.

Standing

Rendered, never written: python3 engine/scripts/check_assessment.py --candidate idea-023 --render

Decision queue

Same render. Worst exposure first; inside a band, cheapest first.

Regrades

None. This is the first statement, and every class was set on 2026-10-04.

What this does not say

• **Nothing here is critical, and that is an artefact of register coverage, not a finding.** B1 US hospitals is graded fatal but reads high. The matrix turns fatal-plus-partial into high, and B1 US hospitals is partial only because register coverage put eleven verified claims under it. None of the eleven settles anything B1 US hospitals could die of:
  • The bundled-payment regulations (claims 29, 65, 66, 67 and 164) verify that **no one pays separately**. They describe B1 US hospitals's constraint. They are not support for B1 US hospitals.
  • Claims 34 and 68 count people and debridement services. They are not irrigations, and not a price.
  • Claims 69 and 105 are a Medicare fee-schedule amount and one retailer's list price on one day.
  • Claims 103 and 104 show that an incumbent holds contracts. They disclose no price. The claims B1 US hospitals would die without are all unconfirmed. claim 161unconfirmed asks whether anyone pays a per-session premium. claim 188unconfirmed asks whether the price covers cost, and no price or bill of materials exists yet. claim 117unconfirmed is claim 161unconfirmed's earlier twin. Read B1 US hospitals as critical. The table is left as rendered, because patching a rendering turns it into a memory.
• B6 Nobody else's rights stop a US sale of the… reads moderate, and most of what lifts it is bad news. Nineteen of its 23 claims are verified. Most of them verify that a patent is in force, or how far its claims reach:
  • the Schultz utility claims run to about 2032-04 claim 181verified, claim 152verified;
  • the Schultz design patents run to about 2037 and 2040 claim 183verified;
  • Medaxis runs to about 2038 claim 185verified;
  • two further leads run to about 2037 and 2040 claim 186verified;
  • two CareFusion applications are pending and unread claim 187verified. The instrument counts a verified threat as support, because it has no column for direction. What B6 Nobody else's rights stop a US sale of the… would die on is counsel's read of a head geometry that does not exist yet claim 63unconfirmed, and that has not happened. On these tags, any US launch before about 2037 sits inside at least one live hardware term. Operations' own declared estimate for launch, which is not a claim, is late 2028 to late 2030. Read B6 Nobody else's rights stop a US sale of the… as high.
• B3 The opened per-patient bag holds, B4 The hand-squeezed head works and is safe to… and B7 Neither half needs more than a 510 read moderate for the same reason, more mildly.
  • B3 The opened per-patient bag holds is lifted by the precedents for the bag and its test plan (claims 119, 122, 125, 169, 176 and 178). P1 per-patient HOCl bag copies them. But neither cleared HOCl bag's summary states an in-use period P1 per-patient HOCl bag could borrow claim 169verified, and every claim about P1 per-patient HOCl bag's own bag is unconfirmed.
  • B4 The hand-squeezed head works and is safe to… is lifted by the published pressure range and the old experimental studies. No head exists to measure claim 63unconfirmed.
  • B7 Neither half needs more than a 510 is lifted by the predicate set. But the only hand-squeezed precedent is a prefilled squeeze bottle cleared as a solution product. It is not a separately sold head claim 179verified. The head's classification claim 180unconfirmed carries more of B7 Neither half needs more than a 510 than its standing shows.
• The grading most open to argument is B2 The single-use head is keyed to this… at reshaping rather than fatal. If the head cannot be keyed to the bag, or buyers refuse a keyed head, the shape that follows is the head sold for anyone's bag. That is a business, but with no pull-through, and it competes head-to-head with every syringe and shield on price. A reader could fairly say that for this organisation the keyed fit is the margin, and grade B2 The single-use head is keyed to this… fatal. It is graded reshaping because neighbour (a) is a real product with a cheaper regulatory route claim 17verified, and the test for reshaping is whether we would still be working on it in a different shape. If B2 The single-use head is keyed to this… is argued up, the argument goes in ## Regrades, not into a quiet edit.
• B1 US hospitals at fatal can be argued down. A bag sold on its own, neighbour (b), survives B1 US hospitals failing. It is graded as no business rather than a different one, for two reasons. The bag is a parity product with HOCl as its preservative claim 119verified. And entry into the solution category is continuing claim 76verified, claim 77verified. That is a judgement about what this organisation would build. It is not a finding.
• B8 The referrer's home market is open. Under… at costly is a US-first grading, and the referrer may not share it. The candidate's launch jurisdiction is the US. Against that business, Denmark failing makes the second market later or dearer, which is costly. For a Danish referrer whose interest is the Danish market, B8 The referrer's home market is open. Under… is the whole question and would be graded fatal. Nothing under B8 The referrer's home market is open. Under… has been checked against a primary source. Every claim is unconfirmed, because no connector reaches European registries, notified-body certificates, TED tender documents or European patents. The US standing says nothing about Denmark.
• B5 Clinicians have a reason to choose it that… at costly is a choice that is easy to argue with. The referrer's original question was whether HOCl beats tap water as the irrigant. This file does not answer it. A 2022 systematic review found no eligible trial of chlorous agents in chronic wounds claim 93verified. No adequately powered trial showing that HOCl beats saline on healing has been confirmed claim 141unconfirmed. And the label cannot make the claim either way claim 10unconfirmed. It is graded costly because in P1 per-patient HOCl bag the bag needs a preservative whatever clinicians believe, and the head sells on pressure and splash. A reader who thinks facilities buy HOCl only because clinicians believe in it would grade B5 Clinicians have a reason to choose it that… reshaping, and would read B1 US hospitals as resting on it.
• The pillars interact, and the arithmetic cannot see it. One connector carries B2 The single-use head is keyed to this…'s keyed fit, B3 The opened per-patient bag holds's resealing port claim 168unconfirmed and part of B6 Nobody else's rights stop a US sale of the…'s unsearched landscape claim 193unconfirmed. A redesign of that connector restarts all three. B4 The hand-squeezed head works and is safe to…'s shield geometry is also an input to B6 Nobody else's rights stop a US sale of the…, because counsel cannot read a claim against a shield that has not been drawn. Standing is computed pillar by pillar, and it has no column for one failure dragging two others down.
• **No pillar came out unexamined, and that is because this file routed the one that would have been.** Before this file, B2 The single-use head is keyed to this…'s engineering and clearance half existed only as the loop record's unstated premise "P1 per-patient HOCl bag-c". It is now claim 195unverified, appended through append_assessment_claims.py as unverified. The front end registered it as A121 in the same sitting. Nobody has checked it. B2 The single-use head is keyed to this… is open because of it, not supported.
• **No pillar is blocking, and no impact review is named, because nothing under any pillar is refuted.** Two claims in the file are refuted, 55 and 153. Both are findings about our own patent lookups, and both rows are closed (A77 Independent claim 19 of US 11,083,835 B2 was superseded by P1 per-patient HOCl bag and rebound as A107, per IR-34 claim 153 came back refuted). Neither is cited here, because neither is in a live register row. The loop's 21 open reviews from the last turn are all commission. This file does not reopen any of them.
• Claims that no pillar cites are not, for that reason, unimportant. The claims behind the seven absorbed register rows (130, 136, 137, 158 and 160 among them) are cited only in prose. claim 158unconfirmed is the competitive-entry count that makes the bag a parity product. Claims 28 to 32 and 33, the reimbursement chain, were left out of the register on purpose, because their falsity would add a payer rather than break anything. Citing them under a pillar would pad it.
• **Exposure is not truth, resolved is not a pass, critical is not bad news, and nothing here ranks idea-023 against another opportunity.** No pillar is resolved.
  • evidence-gated is a state. It says the biggest open questions are knowable, and the queue says which and at what cost. It does not say the opportunity is worth money, or that it is broken.
  • The loop's converged: yes means a human should read the packet. So does this posture.
  • Whether anyone should field the buyer and clinician calls, engage patent counsel, file a 513(g), send the referrer ask, or spend on prototypes and filler requests is Tier 3. Every one of those acts is named here only as the thing that would settle a pillar.

Every claim in the candidate file, with the pillars that rest on it and the materiality it inherits from them. 117 of 212 are read by a pillar; the rest are context — true, possibly checked, and carrying nothing. That is not an insult and it is not an error: it is the only view in this repo that can tell you where the verification effort went.